CytoDyn
CytoDyn Appoints Robert E. Hoffman Chief Executive Officer
CytoDyn announced a leadership change on October 19, 2026. CytoDyn appointed Robert E. Hoffman, who joined as its CFO in May 2025, as CEO, succeeding Dr. Jacob Lalezari, with a focus on clinical execution and financial discipline.
What changed
Robert E. Hoffman was named Chief Executive Officer. Dr. Jacob Lalezari, CEO since November 2023, will remain with the company as Head of Research and Translational Sciences, focusing on new leronlimab opportunities in solid-tumor oncology.
- Leader: Robert E. Hoffman
- Role: Chief Executive Officer
- Effective: October 20, 2026
- Announcement date: October 19, 2026
Leadership background
Hoffman joined CytoDyn as Chief Financial Officer on May 15, 2025, and will continue as the company’s principal accounting officer. His prior roles include President, CEO, interim Chief Financial Officer, and Chairperson of the board at Kintara Therapeutics, and Chief Financial Officer positions at Heron Therapeutics, Innovus Pharmaceuticals, and AnaptysBio. He started at Arena Pharmaceuticals, rising to Senior Vice President, Finance and Chief Financial Officer, and currently serves on the boards of TuHURA Biosciences and Fibrobiologics.
The mandate
CytoDyn said Hoffman cited clinical execution, financial discipline, and positioning the company for its next stage of growth as priorities. Lalezari framed 2027 as a year of clinical results, regulatory progress, and renewed partnering opportunities.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: CytoDyn leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


